The evolving CLL treatment landscape

• Standard therapies for CLL have evolved over the last 10 years that may enable better responses in patients throughout the course of their disease^38,39 (Figure 5)
  • Treatment options have expanded from the single-agent alkylator therapy routinely used in the 1960s and 1970s to the introduction of purine analogs and the standard use of purine analog combination therapy in the 1980s and 1990s.³⁸ Chemoimmunotherapy combining monoclonal antibodies and purine analogs was introduced in the last decade^38,39
• Other therapeutic approaches that aim to improve the quality of patient response and help achieve better clinical outcomes are now being evaluated in preclinical and clinical trials^9,40

Figure 5. The evolution of the CLL therapeutic landscape.^38,39

View References for this site section